The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Chikungunya: What Every Rheumatologist Needs to Know

Chikungunya: What Every Rheumatologist Needs to Know

November 2, 2014 • By Dany V. Thekkemuriyil, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In the past several years, Chikungunya has emerged as a dangerous, rapidly spreading viral illness characterized mainly by debilitating arthritic symptoms. Chikungunya virus (CHIKV) is a single-stranded RNA virus of the genus Alphavirus. The virus is transmitted to humans by mosquitoes. The virus was first isolated from the serum of a febrile patient during an outbreak that occurred in the southern province of Tanzania (Makonde Plateau) in 1952–1953.1,2 The name Chikungunya translates in the Bantu language of the Makonde people to “that which bends up,” in reference to the stooped posture patients frequently adopt due to the frequent and incapacitating associated joint pain. Although initially limited to tropical Africa, South East Asia and the Indian Ocean islands, Chikungunya has spread to Europe and also, recently, to the American continents.3,4

You Might Also Like
  • Cytokine Response Provides Clues to Chikungunya Sequelae
  • Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis
  • Experimental Drug Combination Curbs Chikungunya Arthritis in Mice
Explore This Issue
November 2014

Unlike most other viruses, CHIKV predominantly attacks the joint, and patients present with features similar to inflammatory arthritis. A period of persistent joint symptoms often follows the acute febrile phase, which is indeed difficult to distinguish from rheumatoid arthritis. Many of these cases get referred to rheumatologists, and thus, it’s important to create awareness about arthritis caused by CHIKV. This article describes the risk associated with the spread of this infection and clinical features, mainly focusing on rheumatic manifestations.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

How Far Has This Viral Infection Spread?

Although there have been reports of epidemics with fevers and predominant arthritis symptoms in the early 19th century, they were thought to be dengue fever. But it’s now felt they would better fit the presentation of Chikungunya infection.5 Since 1952, Chikungunya has been frequently reported in the African continent, and the first reported outbreak in Asia was in Thailand in 1958. Since then, a number of cases were reported from 1960 to 2000 in Africa and Asia.6,7

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Thekkemuriyil
Dr. Thekkemuriyil

But it was in 2005 when this viral outbreak caught global attention with the rapid spread of devastating outbreaks in the Indian Ocean islands. It was most notable in the Reunion Islands, affecting around 266,000 individuals (34% of the island’s population) and 75% of the population of Lamu (an island off the coast of Kenya).8,9 The French Territories in the Indian Ocean had more extensive administrative and technological resources than other islands in the region, so they had better local epidemic-monitoring systems. In India, nearly 1.4 million suspected cases of Chikungunya were reported in 2006.10,11

Although considered a tropical disease, an outbreak of Chikungunya occurred in northeastern Italy in 2007, resulting in more than 200 locally acquired cases.12 The index case was a traveler returning to Europe from India. Phylogenetic analysis of the virus demonstrated similarity with the Chikungunya strain found in the Indian Ocean outbreaks. This is an example for seasonal synchrony in which the period of active transmission in India coincided with Italy’s hottest months. It shortened the extrinsic incubation period, resulting in the early transmission of the virus to a new host.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Education & Training, Professional Topics Tagged With: chikungunya, patient care, rheumatologist, Safety, Steroids, symptom, Thekkemuriyil, TreatmentIssue: November 2014

You Might Also Like:
  • Cytokine Response Provides Clues to Chikungunya Sequelae
  • Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis
  • Experimental Drug Combination Curbs Chikungunya Arthritis in Mice
  • Chikungunya Fever May Trigger Chronic Articular Symptoms

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)